Lidoderm is a medicated plaster containing 5% lidocaine, and was developed by Endo Pharmaceuticals. Lidocaine is an amide-type local anesthetic agent that acts by stabilizing neuronal membranes. It impairs membrane permeability to sodium, which in turn blocks impulse propagation, and thus dampens both peripheral nociceptor sensitization and eventually central nervous system hyperexcitability. It also suppresses neuronal discharge in A delta and C fibers. Lidocaine is also used as an anesthetic agent indicated for production of local or regional anesthesia, and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases.
LIST OF FIGURES
8 Figure 1: Lidoderm for neuropathic pain – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Lidoderm for neuropathic pain
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Lidoderm for neuropathic pain
12 Figure 4: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES 5 Table 1: Lidoderm drug profile
7 Table 2: Lidoderm Phase III data in neuropathic pain syndromes
13 Table 3: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726